Evidence map›Paper›PMID 32529966›Full record

ArticleJournal of psychoactive drugs

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.

Jason B Luoma, Christina Chwyl, Geoff J Bathje, Alan K Davis, Rafael Lancelotta

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 8 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 8 syntheses or guidelines pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Pharmacokinetics of N,N-dimethyltryptamine in Humans.European journal of drug metabolism and pharmacokinetics · 2023
    Trial
  11. Canadian family physician Medecin de famille canadien · 2026
    Review
  12. Psychedelic-assisted psychotherapy: Emerging paradigm.Canadian family physician Medecin de famille canadien · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jason B LuomaPortland Psychotherapy Clinic, Research, & Training Center , Portland, OR, USA.ORCID 0000-0002-3601-7037
Christina ChwylPortland Psychotherapy Clinic, Research, & Training Center , Portland, OR, USA.
Geoff J BathjeDepartment of Clinical Mental Health Counseling, Adler University , Chicago, IL, USA.
Alan K DavisCollege of Social Work, The Ohio State University , Columbus, OH, USA.ORCID 0000-0003-4770-8893
Rafael LancelottaInnate Path Psychotherapy Clinic , Lakewood, CO, USA.
Oregon Clinic · USAdler University · USJohns Hopkins University · US

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
NIDA NIH HHS T32 DA007209
6 · The paper itself

Abstract

After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD (lysergic acid diethylamide), ayahuasca (which contains a combination of N,N-dimethyltryptamine and harmala monoamine oxidase inhibitor alkaloids), and MDMA (3,4-methylenedioxymethamphetamine). We compared the standardized mean difference between the experimental and placebo control group at the primary endpoint. Results indicated a significant mean between-groups effect size of 1.21 (Hedges

Indexed as

BanisteriopsisHallucinogensN-Methyl-3,4-methylenedioxyamphetamineAdultHumansLysergic Acid DiethylamidePsilocybinHallucinogensLysergic Acid DiethylamideN-Methyl-3,4-methylenedioxyamphetaminePsilocybinmeta-analysisplacebo-controlledPsychedelicsrandomized clinical trialsreview

Identifiers

PMID32529966
PMCPMC7736164
OpenAlexW3035643259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.